Nanocarriers deliver anti-inflammatory therapeutics across the blood-brain barrier to activated microglia
Background Delivering therapeutics to the brain remains a major drug-development challenge because the blood-brain barrier restricts systemic agents from reaching therapeutically relevant concentrations in the central nervous system. This barrier is especially problematic for conditions involving hypothalamic inflammation, where therapeutics must not only enter the brain but also reach activated microglia, immune cells that contribute to inflammatory signaling and appetite dysregulation. The published study and OSU Newsroom describe cancer cachexia as a serious wasting syndrome associated with advanced cancers, including pancreatic cancer, and identify hypothalamic inflammation as a key contributor to disrupted appetite and metabolism.
Current approaches for systemic anti-inflammatory therapy are limited by poor blood-brain barrier penetration and limited cell-type targeting. The OSU technology addresses this gap with a nanocarrier platform designed to transport anti-inflammatory payloads across the blood-brain barrier and preferentially deliver them to activated microglia in inflamed hypothalamic tissue.
Technology Description This technology is a dual-targeted polymeric nanocarrier platform for systemic delivery of anti-inflammatory therapeutics to the brain, with a demonstrated focus on hypothalamic neuroinflammation and cancer-associated cachexia. The platform uses a polymeric nanocarrier architecture engineered with two targeting functions: one to support blood-brain barrier penetration and one to support interaction with activated microglia. In the published proof-of-concept studies, the nanocarriers were loaded with zimlovisertib, an IRAK4 inhibitor, to suppress inflammatory signaling in target tissue.
At a high level, the nanocarrier is designed to encapsulate poorly water-soluble small-molecule payloads, circulate after intravenous administration, cross the blood-brain barrier, accumulate in the hypothalamus, and release payload intracellularly in response to the reducing environment found inside target cells. The manuscript reports that the nanocarrier system uses a biodegradable polymeric core-shell design, supports hydrophobic payload loading, and exhibits glutathione-responsive release behavior. Public listing language should avoid disclosing precise formulation ratios, peptide sequences, manufacturing conditions, or unpublished optimization details unless approved by patent counsel.
The technology has been demonstrated in multiple preclinical systems. In an in vitro blood-brain barrier/microglia co-culture model, dual-functionalized nanocarriers showed enhanced uptake by pro-inflammatory microglia after crossing an endothelial barrier model. In mouse studies, the nanocarriers accumulated in brain and hypothalamic tissue after intravenous administration and showed evidence of microglial targeting by immunohistochemistry. In an acute lipopolysaccharide-induced neuroinflammation model, treatment reduced inflammatory markers and improved food intake and body-weight measures. In a pancreatic cancer-associated cachexia mouse model, treatment improved food intake, body-weight maintenance, and muscle preservation relative to controls.
Preclinical proof of concept has been demonstrated in laboratory models and relevant mouse disease models.
Evidence / Validation: Dual-targeted nanocarriers increased brain and hypothalamus accumulation compared with non-targeted or single-targeted controls, including 1.4-fold higher brain and 1.8-fold higher hypothalamic signal compared with the blood-brain-barrier-targeted formulation in an acute neuroinflammation model. In the pancreatic cancer cachexia model, dual-targeted nanocarriers showed 4.1-fold higher brain and 3.0-fold higher hypothalamic signal compared with non-targeted controls. Treatment studies reported reduced pro-inflammatory cytokine expression, increased food intake, improved body-weight maintenance, and reduced cachexia-associated gastrocnemius muscle loss by approximately 50% relative to controls.
Figure 1: Dual-targeting nanocarriers
Benefits
Applications
Opportunity OSU is seeking partners to advance a preclinical nanocarrier platform for targeted brain delivery of anti-inflammatory therapeutics. The most appropriate near-term opportunities are licensing, co-development, sponsored research, and preclinical validation partnerships with companies active in CNS drug delivery, neuroinflammation, cancer cachexia, supportive oncology, or nanomedicine formulation development.
A partner could help optimize payload selection, formulation robustness, manufacturability, pharmacokinetics, biodistribution, repeat-dose safety, and efficacy in additional disease models. Longer-term development would likely require IND-enabling toxicology, scalable CMC, regulatory strategy, and assessment of whether the platform should be developed as a standalone cachexia therapeutic, a CNS delivery platform, or a payload-specific product candidate.
Third-party payload considerations: Zimlovisertib/PF-06650833 is an IRAK4 inhibitor previously studied by a large pharmaceutical company; freedom to operate and rights to commercialize any zimlovisertib-containing product should be reviewed separately from OSU’s nanocarrier IP.
Status U.S. Provisional Patent Application No. 63/845,304